Clinical trials: Helicobacter Pylori, open to volunteers
Helicobacter Pylori Infection
P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based…
- Trial name
- PRO-HP (NCT07285096)
- Testing
- Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstances，not involve any intervention procedures
- Where
- China
- Volunteers
- 1,730 people
- Sponsor
- Yueyue Li
Gastric (Stomach) Cancer
Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test
This is a multicenter, cross-sectional study. It is based on fecal methylation site detection, H. pylori susceptibility testing of fecal samples, and a combination of the two, compared with the "gold standard" imaging tests, CT…
- Trial name
- NCT06943768
- Testing
- fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing
- Volunteers
- 9,654 people, healthy volunteers welcome
- Sponsor
- Fudan University
Helicobacter Pylori, Early Gastric Cancer
Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
This multicenter retrospective and prospective real-world observational study will evaluate the relationship of Helicobacter pylori (H.
- Trial name
- NCT07724496
- Testing
- 13C-Urea Breath Test, Serum Helicobacter pylori Antibody Testing, Pathological Assessment of Gastric Tissue
- Where
- 3 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Chinese PLA General Hospital
Gastric (Stomach) Cancer
Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high…
- Trial name
- NCT06943794
- Testing
- recommendations for Hp eradication treatment
- Where
- China
- Volunteers
- 4,824 people, healthy volunteers welcome
- Sponsor
- Fudan University
Helicobacter Pylori Infection, Helicobacter Pylori Associated Gastrointestinal Disease
Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea
To assess antimicrobial resistance rates and minimal inhibitory concentrations in H. pylori isolated from patients with upper gastrointestinal disease with long-term period.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Associated Gastrointestinal Disease, Helicobacter Pylori Infection, Susceptibility to, Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation
- Trial name
- NCT05247112
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Infection, Vonoprazan
Efficacy Comparison of 10-Day High-Dose Versus 14-Day Standard-Dose Vonoprazan Plus Amoxicillin in Helicobacter Pylori Eradication: A Multicenter Non-Inferiority Randomized Controlled Trial
This is a multicenter non-inferiority randomized controlled trial for patients infected with Helicobacter pylori. Eligible participants will be randomly split into two groups.
- Conditions
- Helicobacter Infection, Vonoprazan, Amoxicillin
- Trial name
- NCT07720037
- Testing
- 10-day group, 14-day group
- Volunteers
- 232 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection, Helicobacter Pylori Gastritis
Helicobacter Pylori Local Prevalence and Antibiotic Resistance
The clinical management of H. pylori infection depends essentially on two factors, prevalence and local resistance. In Germany, only limited data from rather small cohorts currently exist regarding both factors.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Gastritis, Drug Resistant Bacterial Infection, Antibiotic Resistant Infection
- Trial name
- HelicoPTER (NCT05561504)
- Where
- Germany
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
H Pylori
Psychological Effects of H Pylori Associated Gastritis
The goals of this study 1. Explore association between psychological factors and Hpylori associated gastritis. 2. Assess prevalence and severity of psychology symptoms among patients with H pylori associated gastritis and their…
- Trial name
- NCT06632210
- Volunteers
- 130 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without…
- Trial name
- NCT07439445
- Testing
- Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Helicobacter Pylori Infection, Dyspepsia
Pylori Duo for Adjunctive Treatment and Prevention of Recurrence of Helicobacter Pylori Infection
This randomized, double-blind, placebo-controlled, single-center clinical trial will evaluate the efficacy and safety of Pylori Duo as an adjunctive treatment in adult patients with confirmed Helicobacter pylori infection.
- Conditions
- Helicobacter Pylori Infection, Dyspepsia, Gastrointestinal Adverse Effects
- Trial name
- NCT07729293
- Testing
- Omeprazole, Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole, Pylori Duo
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Gala Servicios Clinicos S.L.
HELICOBACTER PYLORI INFECTIONS
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
this Study Evaluating Safety and Effectiveness of (Proton Pump Inhibitor versus Vonoprazan) Based Triple Therapy with or without Zinc to Eradicate H. pylori Infection
- Trial name
- NCT07275827
- Testing
- zinc sulfate, Vonoprazan + amoxicillin + clarithromycin, proton pump inhibitor + amoxicillin
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Tanta University
Helicobacter Pylori
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy
The 2024 American College of Gastroenterology (ACG) Clinical Guideline recommends a 14-day vonoprazan-amoxicillin (VA) regimen, consisting of vonoprazan 20 mg twice daily with amoxicillin 1000 mg three times daily, as a…
- Trial name
- JSHERO4 (NCT07232095)
- Testing
- VAB-7, VA-14
- Where
- China
- Volunteers
- 316 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Helicobatcer Pylori, First-Line Eradication
Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori Infection
Most international treatment guidelines currently recommend a 14-day bismuth quadruple therapy as the first-line treatment for Helicobacter pylori infection, especially in areas with high clarithromycin resistance.
- Trial name
- NCT07788053
- Testing
- Bismuth, Bismuth quadruple therapy
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chih-An Shih, MD
Helicobacter Pylori Eradication
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2.
- Trial name
- NCT06349486
- Testing
- vonoprazan, amoxicillin, tripotassium dicitrate bismuthate, vonoprazan, amoxicillin, rabeprazole, amoxicillin, clarithromycin
- Where
- Taiwan
- Volunteers
- 390 people
- Sponsor
- Kaohsiung Medical University
Helicobacter Pylori Infection
Pathogen-microbiome Interaction During Helicobacter Pylori Infection
Helicobacter pylori affects the gut microbiome in ways that are only partially understood. In which patients H. pylori causes severe disease and in whom it merely colonizes, possibly even with beneficial effects, is not…
- Trial name
- PREDICTHP (NCT05121025)
- Testing
- Analysis of gut microbiome and immune signatures
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University Hospital Freiburg
Oncology Epidemiology, Risk Factors
Prevalence of H. Pylori in Stomach Cancers in the West Indies
The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations.
- Trial name
- PyloCaGe (NCT07233447)
- Where
- 2 sites in Guadeloupe
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
HELICOBACTER PYLORI INFECTIONS
Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）
This study is designed to evaluate two different tegoprazan-based dual therapy regimens for the treatment of Helicobacter pylori (H. pylori) infection.
- Trial name
- FAST-HP (NCT07242443)
- Testing
- Tegoprazan 50 mg, Amoxicillin 1 g TID, Amoxicillin 1.5 g BID
- Where
- China
- Volunteers
- 240 people
- Sponsor
- First People's Hospital of Hangzhou
H.Pylori Gastrointestinal Disease, H Pylori Infection
Argentinean Registry on the Management of Helicobacter Pylori Infection
Helicobacter pylori (H pylori) is the main cause of chronic gastritis and peptic ulcer disease. In addition, is the main risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma.
- Trial name
- ArgReg-Hp (NCT06579365)
- Where
- Argentina
- Volunteers
- 5,000 people
- Sponsor
- University of Buenos Aires
HELICOBACTER PYLORI INFECTIONS
Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori
This prospective observational study aims to evaluate the feasibility and performance of real-time PCR (qPCR) performed on formalin-fixed, paraffin-embedded (FFPE) gastric biopsies to detect Helicobacter pylori infection and…
- Trial name
- HED-2T (NCT07821294)
- Testing
- q-PCR on FFPE gastric biopsies
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Clinique Bizet
H. Pylori Infection
European Registry on the Management of Helicobacter Pylori Infection
The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical…
- Trial name
- NCT02328131
- Where
- 30 sites in Austria, Belgium and 28 more
- Volunteers
- 10,000 people
- Sponsor
- Javier P. Gisbert